At a glance
- Originator Biomedica Foscama
- Class Anti-ischaemics; Small molecules
- Mechanism of Action Antioxidants; Lipid peroxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Reperfusion injury
Most Recent Events
- 25 Oct 2005 IRFI 042 is no longer available for licensing
- 20 Oct 2005 Discontinued - Preclinical for Atherosclerosis in Italy (PO)
- 20 Oct 2005 Discontinued - Preclinical for Reperfusion injury in Italy (PO)